Analyst Ratings February 12, 2026

Laidlaw Sticks With Buy on Viking Therapeutics After Q4 2025 Results, Eyes VK2735 Pathways

Analyst retains $110 target as company advances oral and subcutaneous VK2735 programs despite a sizable Q4 earnings shortfall

By Priya Menon VKTX
Laidlaw Sticks With Buy on Viking Therapeutics After Q4 2025 Results, Eyes VK2735 Pathways
VKTX

Laidlaw Securities reaffirmed a Buy rating on Viking Therapeutics (VKTX) and set a $110 price target after the company reported fourth-quarter 2025 financial results and corporate updates. The firm highlighted clearer development paths for VK2735 in both subcutaneous and oral forms and noted Viking's strong cash position. The company also reported a significant earnings-per-share miss for the quarter, underscoring near-term execution risks for investors.

Key Points

  • Laidlaw reaffirmed a Buy rating on Viking Therapeutics and set a $110 price target, implying substantial upside from the current $28.55 share price.
  • Laidlaw highlighted clearer development plans for VK2735: completion of VANQUISH studies for the subcutaneous formulation and initiation of Phase III for the oral formulation in H2 2026, with possible topline results in 2028.
  • InvestingPro data show analyst targets ranging $36 to $125 and indicate Viking holds more cash than debt with a current ratio of 28.34, supporting planned development activity.

Laidlaw Securities has reiterated its Buy recommendation on Viking Therapeutics (NASDAQ:VKTX), maintaining a $110.00 price target after the biotech released its fourth-quarter 2025 financial results and accompanying corporate updates. The target implies substantial upside relative to the current market price of $28.55 and sits alongside a broader analyst consensus score of 1.39, categorized as Strong Buy.

The research house emphasized what it sees as more defined clinical pathways for VK2735, Viking’s investigational obesity treatment. Laidlaw noted that the company intends to complete the VANQUISH studies evaluating the subcutaneous formulation of VK2735 while also advancing an oral formulation into Phase III testing in the second half of 2026. Laidlaw projected that topline results from the oral Phase III could potentially be available in 2028.

Laidlaw additionally pointed to strategic development options under consideration, including the exploration of maintenance regimens as part of the treatment approach for VK2735. The firm underscored the addition of experienced commercial management to Viking’s team as a constructive step that could broaden pathways to realize the program’s shareholder value.

Financially, InvestingPro data cited by analysts shows Viking holding more cash than debt and reporting a current ratio of 28.34, a liquidity profile Laidlaw said supports the company’s planned development activities.

Viking disclosed its quarter and corporate update on Thursday after the market close. The company reported an earnings per share (EPS) of -$1.38 for the fourth quarter of 2025, missing the forecasted -$0.9 and amounting to a 53.33% negative surprise versus expectations. Despite the shortfall in earnings, Viking stated it will continue pursuing its strategic objectives in the obesity treatment market, leveraging its product pipeline as the driver of future growth.

Analyst target ranges reported via InvestingPro span from $36 to $125, indicating a wide range of expectations among market participants. Laidlaw’s $110 target situates toward the upper end of that distribution.


Context for investors

The combination of an ambitious price target, clarified clinical timelines for VK2735, and an apparent liquidity cushion form the basis for Laidlaw’s maintained Buy rating. At the same time, the recent quarterly earnings miss underscores that operational execution and near-term financial performance remain areas of investor attention.

Risks

  • Significant quarterly earnings shortfall: Viking reported Q4 2025 EPS of -$1.38 versus a forecasted -$0.9, a 53.33% negative surprise, creating near-term financial performance risk for investors. Impacted sectors: financial markets, biotech equities.
  • Clinical and timeline uncertainty: Laidlaw’s estimate that oral Phase III topline results could be available in 2028 and the need to complete VANQUISH studies mean outcomes and timing depend on successful trial execution. Impacted sectors: biotechnology, healthcare.
  • Execution risk around commercialization: while Viking added experienced commercial management, translating clinical progress into commercial success and shareholder value is not guaranteed. Impacted sectors: pharmaceuticals, healthcare services.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026